RARX - ラ・ファ―マシュ―ティカルズ (Ra Pharmaceuticals Inc.)

RARXのニュース

   Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?  2020/04/02 15:30:10 Zacks Investment Research
Is (RARX) Outperforming Other Medical Stocks This Year?
   The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests  2020/04/01 11:38:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) Athersys Inc (NASDAQ: ATHX ) Forty Seven Inc (NASDAQ: FTSV ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Quidel Corporation (NASDAQ: QDEL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 31) Aikido Pharma Inc (NASDAQ: AIKI ) BIOLASE Inc (NASDAQ: BIOL ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Gritstone Oncology Inc (NASDAQ: GRTS ) Neovasc Inc (NASDAQ: NVCN )(moved in reaction to its fourth quarter results) Opko Health Inc. (NASDAQ: OPK ) Phio Pharmaceuticals Corp (NASDAQ: PHIO )(announced $4 million registered offering) Second Sight Medical Products Inc (NASDAQ: EYES ) Related Link: Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment Stocks In Focus Inflarx Begins Human Testing Of Lead Drug For COVID-19-induced Pneumonia German biopharma Inflarx NV (NASDAQ: IFRX ) said it has enrolled and dosed the first patient into a randomized clinical trial investigating the safety and efficacy of IFX-1 , its monoclonal anti-C5a antibody in patients with severe COVID-19-induced pneumonia.
   Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update  2020/02/27 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the fourth quarter and year ended December 31, 2019, and provided an update on recent corporate and clinical developments. “2019 was a transformational year for Ra Pharma in our efforts to discover, develop, and expand access to important therapies for patients with rare diseases, including the strengthening of our balance sheet with a $150 million financing and the advancement of key
   Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology  2020/02/18 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA Neurology. The JAMA Neurology publication can be accessed here. “This publication in JAMA Neurology recognizes the impact and significance of the findings from our Phase 2 clinical trial demonstrating zilucoplan’s potential in gMG, a chronic and debilitating neu
   Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial  2020/01/22 14:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the U.S. Food and Drug Administration’s (FDA) clearance of the Investigational New Drug (IND) application for the HEALEY ALS Platform Trial for the treatment of amyotrophic lateral sclerosis (ALS). Zilucoplan was selected as one of the first clinical candidates to be evaluated in this platform trial for ALS led by the Sean M. Healey & AMG Center for ALS at Mass General. “We are pleased that the FDA has
   Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?  2020/04/02 15:30:10 Zacks Investment Research
Is (RARX) Outperforming Other Medical Stocks This Year?
   The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests  2020/04/01 11:38:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) Athersys Inc (NASDAQ: ATHX ) Forty Seven Inc (NASDAQ: FTSV ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Quidel Corporation (NASDAQ: QDEL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 31) Aikido Pharma Inc (NASDAQ: AIKI ) BIOLASE Inc (NASDAQ: BIOL ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Gritstone Oncology Inc (NASDAQ: GRTS ) Neovasc Inc (NASDAQ: NVCN )(moved in reaction to its fourth quarter results) Opko Health Inc. (NASDAQ: OPK ) Phio Pharmaceuticals Corp (NASDAQ: PHIO )(announced $4 million registered offering) Second Sight Medical Products Inc (NASDAQ: EYES ) Related Link: Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment Stocks In Focus Inflarx Begins Human Testing Of Lead Drug For COVID-19-induced Pneumonia German biopharma Inflarx NV (NASDAQ: IFRX ) said it has enrolled and dosed the first patient into a randomized clinical trial investigating the safety and efficacy of IFX-1 , its monoclonal anti-C5a antibody in patients with severe COVID-19-induced pneumonia.
   Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update  2020/02/27 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the fourth quarter and year ended December 31, 2019, and provided an update on recent corporate and clinical developments. “2019 was a transformational year for Ra Pharma in our efforts to discover, develop, and expand access to important therapies for patients with rare diseases, including the strengthening of our balance sheet with a $150 million financing and the advancement of key
   Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology  2020/02/18 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA Neurology. The JAMA Neurology publication can be accessed here. “This publication in JAMA Neurology recognizes the impact and significance of the findings from our Phase 2 clinical trial demonstrating zilucoplan’s potential in gMG, a chronic and debilitating neu
   Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial  2020/01/22 14:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the U.S. Food and Drug Administration’s (FDA) clearance of the Investigational New Drug (IND) application for the HEALEY ALS Platform Trial for the treatment of amyotrophic lateral sclerosis (ALS). Zilucoplan was selected as one of the first clinical candidates to be evaluated in this platform trial for ALS led by the Sean M. Healey & AMG Center for ALS at Mass General. “We are pleased that the FDA has
   Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?  2020/04/02 15:30:10 Zacks Investment Research
Is (RARX) Outperforming Other Medical Stocks This Year?
   The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests  2020/04/01 11:38:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) Athersys Inc (NASDAQ: ATHX ) Forty Seven Inc (NASDAQ: FTSV ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Quidel Corporation (NASDAQ: QDEL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 31) Aikido Pharma Inc (NASDAQ: AIKI ) BIOLASE Inc (NASDAQ: BIOL ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Gritstone Oncology Inc (NASDAQ: GRTS ) Neovasc Inc (NASDAQ: NVCN )(moved in reaction to its fourth quarter results) Opko Health Inc. (NASDAQ: OPK ) Phio Pharmaceuticals Corp (NASDAQ: PHIO )(announced $4 million registered offering) Second Sight Medical Products Inc (NASDAQ: EYES ) Related Link: Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment Stocks In Focus Inflarx Begins Human Testing Of Lead Drug For COVID-19-induced Pneumonia German biopharma Inflarx NV (NASDAQ: IFRX ) said it has enrolled and dosed the first patient into a randomized clinical trial investigating the safety and efficacy of IFX-1 , its monoclonal anti-C5a antibody in patients with severe COVID-19-induced pneumonia.
   Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update  2020/02/27 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the fourth quarter and year ended December 31, 2019, and provided an update on recent corporate and clinical developments. “2019 was a transformational year for Ra Pharma in our efforts to discover, develop, and expand access to important therapies for patients with rare diseases, including the strengthening of our balance sheet with a $150 million financing and the advancement of key
   Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology  2020/02/18 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA Neurology. The JAMA Neurology publication can be accessed here. “This publication in JAMA Neurology recognizes the impact and significance of the findings from our Phase 2 clinical trial demonstrating zilucoplan’s potential in gMG, a chronic and debilitating neu
   Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial  2020/01/22 14:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the U.S. Food and Drug Administration’s (FDA) clearance of the Investigational New Drug (IND) application for the HEALEY ALS Platform Trial for the treatment of amyotrophic lateral sclerosis (ALS). Zilucoplan was selected as one of the first clinical candidates to be evaluated in this platform trial for ALS led by the Sean M. Healey & AMG Center for ALS at Mass General. “We are pleased that the FDA has

calendar